

If the following information is not complete, correct, or legible, the SA process can be delayed.  
Please use one form per member.

**MEMBER INFORMATION****Last name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**First name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Medicaid ID number:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Date of birth:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Gender:** ☐ Male ☐ Female**PRESCRIBER INFORMATION****Last name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**First name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**NPI number:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Phone number:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Fax number:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Is the drug prescribed by or in consultation with a specialty?**☐ Endocrinologist ☐ Nephrologist**DRUG INFORMATION****Drug name/Form:** \_\_\_\_\_**Strength:** \_\_\_\_\_**Quantity per day:** \_\_\_\_\_**All growth hormone medications require the submission of a Clinical Service Authorization****Preferred medications:**☐ Genotropin<sup>®</sup> ☐ Norditropin FlexPro<sup>®</sup>**Non-Preferred medications:**

<input type="checkbox"/> Humatrope <sup>®</sup> cartridge/vial	<input type="checkbox"/> Nutropin AQ <sup>®</sup> NuSpin <sup>®</sup>	<input type="checkbox"/> Nutropin AQ <sup>®</sup> cartridge/vial
<input type="checkbox"/> Omnitrope <sup>®</sup> cartridge/vial	<input type="checkbox"/> Saizen <sup>®</sup> cartridge/vial	<input type="checkbox"/> Serostim <sup>®</sup> vial
<input type="checkbox"/> Skytrofa <sup>™</sup> Syringe	<input type="checkbox"/> Zomacton <sup>®</sup> vial	<input type="checkbox"/> Zorbtive <sup>®</sup> vial

**If requesting a non-preferred agent, please document why a preferred agent cannot be used:**

(Form continued on next page.)

Member's last name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Member's first name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**CRITERIA**

1. What is the diagnosis?

☐ Idiopathic short stature (ISS)☐ Noonan syndrome (NS)☐ SHOX deficiency (SHOXD)☐ Adult GH deficiency☐ Prader Willi syndrome (PWS)☐ Chronic renal insufficiency☐ Other: \_\_\_\_\_☐ Pediatric growth hormone (GH) deficiency☐ Familial short stature☐ Small for gestational age (SGA)☐ Turner syndrome (TS)☐ Short bowel syndrome (SBS),**skip to diagnosis section**☐ Pediatric chronic kidney disease,**skip to diagnosis section**

2. Is this request for a new start, restart (re-initiation) or continuation of Growth Hormone (GH) therapy?

☐ New start, **skip to diagnosis section**☐ Restart, **skip to diagnosis section**☐ Continuation

3. Is the member's growth velocity at least 2 cm per year while on GH therapy?

☐ Yes☐ No**Action required:** If YES, please attach documentation from medical record supporting growth velocity of at least 2 cm/year.

4. Are the growth plates open?

☐ Yes☐ No

5. What is the member's current height? Age: Years \_\_\_\_\_ Months \_\_\_\_\_ Height: \_\_\_\_\_ inches

**Action required:** Please attach documentation from the medical record of current height.**DIAGNOSIS AND MEDICAL INFORMATION****Complete the following section(s), based on the Member's diagnosis. Complete all that apply:****Section A: All pediatric indications**

6. What is the member's pretreatment height and age?

Age: Years \_\_\_\_\_ Months \_\_\_\_\_ Height: \_\_\_\_\_ inches

**Action required:** Please attach documentation from the medical record showing pretreatment height and age at measurement.

7. Which of the following criteria does the member's pretreatment height meet?

☐ Greater than or equal to 2.25 standard deviations (SD) below the mean for age and gender☐ Greater than or equal to 2 standard deviations (SD) below the mean for age and gender

(Form continued on next page.)

**Member's last name:****Member's first name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

8. What is the member's pretreatment growth velocity?

☐ Greater than 1 standard deviation (SD) below the mean for age and gender☐ 1 SD below the mean for age and gender**Action required:** *Please attach documentation from the medical record showing either.*☐ At least 2 heights measured by an endocrinologist at least 6 months apart  
(data for at least 1 year)☐ At least 4 heights measured by a primary care physician at least 6 months apart  
(data for at least 2 years)**Section B: Pediatric GH Deficiency**

9. Did the member have a GH response of less than 10 ng/mL (or otherwise abnormal as determined by the lab) of at least 2 GH stimulation tests LFTs?

☐ Yes☐ No**Action required:** *If YES, please attach documentation of stimulation test results.*

10. Did member have a GH response of less than 15 ng/mL on at least 1 GH stimulation test?

☐ Yes☐ No**Action required:** *Please attach documentation of GH stimulation test result. If YES, indicate results.*

11. Does the member have a defined CNS pathology, history of cranial irradiation or genetic condition associated GH deficiency?

☐ Yes☐ No

12. Does the member have both IGF-1 and IGFBP-3 levels below normal for age and gender?

☐ Yes☐ No**Action required:** *If YES, please attach documentation from the medical record showing IGF-1 and IGFBP-3 levels below normal.*

13. Does the member have 2 or more documented pituitary hormone deficiencies other than GH?

☐ Yes☐ No

14. Did the member have an abnormally low GH level in association with neonatal hypoglycemia?

☐ Yes☐ No**Action required:** *If YES, please attach documentation of GH level.***Section C: Pediatric Chronic Kidney Disease/Chronic Renal Insufficiencies**

15. Does the member have any of the following? Indicate any/all the apply:

☐ Creatinine clearance of 75 mL/min/1.73 m<sup>2</sup> or less☐ Dialysis dependency☐ Serum creatinine greater than 3.0 g/dL☐ None of the above*(Form continued on next page.)*

Member's last name:

Member's first name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Section D: Pediatric Chronic Kidney Disease**

16. Is this request for a new start, restart (re-initiation) or continuation of GH therapy?

☐ New start, *no further questions*
☐ Restart
 ☐ Continuation

17. Was GH therapy previously approved for this member?

☐ Yes
 ☐ No

18. What is the member's current height in inches? \_\_\_\_\_

**Action required:** *Please attach documentation from the medical record of current height.*  
*If Restart, no further questions.*

19. Is the member's growth velocity at least 2 cm per year while on GH therapy?

☐ Yes
 ☐ No

**Action required:** *If YES, please attach documentation from medical record supporting growth velocity of at least 2 cm/year. (Form continued on next page.)*

**Section E: Adult GH Deficiency**

20. Does the member have irreversible hypothalamic/pituitary structural lesions or ablation?

☐ Yes
 ☐ No
 ***If YES, no further questions.***

21. Does the member have a defect in GH synthesis?

☐ Yes
 ☐ No
 ***If YES, no further questions.***

22. Did the member have GH deficiency diagnosed during childhood?

☐ Yes
 ☐ No

23. Does the member have 3 or more pituitary hormone deficiencies?

☐ Yes
 ☐ No

24. Was the member retested for GH deficiency after an at least 1-month break in GH therapy?

☐ Yes
 ☐ No

25. Which of the following pharmacologic agents was used in a GH stimulation test to measure peak GH levels?

☐ Insulin
 ☐ Clonidine
 ☐ Levodopa
 ☐ Glucagon
 ☐ Arginine  
☐ GH stimulation test not performed
 ☐ Other: \_\_\_\_\_

**Action required:** *Please attach documentation showing the results of GH stimulation test.*

26. Indicate the peak GH level: \_\_\_\_\_ ng/mL

27. Is the pretreatment IGF-1 level below the laboratory's range of normal?

☐ Yes
 ☐ No

**Action required:** *Please attach documentation from the medical record showing the member's pretreatment IGF-1 level.*

(Form continued on next page.)

**Member's last name:**

**Member's first name:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**Section F: Short Bowel Syndrome**

28. Is the member receiving specialized nutritional support?

☐ Yes ☐ No

29. Will GH be used in conjunction with optimal management of short bowel syndrome?

☐ Yes ☐ No

30. How many months of GH therapy has the member received? \_\_\_\_\_ months

☐ Not applicable/New start

---

**Prescriber signature (Required)**

**Date**

By signature, the Physician confirms the above information is accurate and verifiable by member records.

**Please include ALL requested information; incomplete forms will delay the SA process.**

Submission of documentation does NOT guarantee coverage by Molina Healthcare.

The completed form may be **faxed to 1-844-278-5731**, or you may call **(800) 424-4518. (TTY: 711)**